Aging clock test: tirzepatide trial targets biological age

NCT ID NCT07220473

Recruiting now Disease control Sponsor: The University of Texas Medical Branch, Galveston Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether tirzepatide (Zepbound), a drug already used for weight loss, can slow biological aging in adults aged 55 to 70. Ninety participants with a BMI of 27 or higher will be randomly assigned to receive the drug weekly for 24 weeks or no drug, followed by 12 weeks off treatment. The main focus is on changes in DNA-based aging markers, not weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirzepatide (Zepbound), a weekly injection for weight loss
What this could lead to: If it works, this could point toward a way to slow biological aging and improve health in older adults using an existing weight-loss drug.
What could go wrong: This is a small, early-phase pilot study (90 people) with no placebo control—just a no-drug group. The results may not apply to everyone, and the drug's long-term effects on aging are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING LONGEVITY 1

Contacts and locations

Locations

University of Texas Medical Branch
RECRUITING

Galveston, Texas, 77555, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.